Speakers

November 12 – 14, 2024 • Joseph B. Martin Conference Center, Boston, MA

Speakers


Edward Abrahams, Ph.D.

President

Personalized Medicine Coalition

Edward Abrahams is the President of the Personalized Medicine Coalition. Representing innovators, scientists, patients, providers, and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services, and products for the benefit of patients and health systems. It has grown from its original 18 founding members in 2004 to more than 225 today.

 

Antonio L. Andreu, M.D., Ph.D.

Scientific Director

European Infrastructure for Translational Medicine

Toni is an M.D., Ph.D., who specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research. He has served previously as the Director of the Spanish National Institute of Health, Carlos III, creating the national program for personalized medicine.

Christina Annunziata, M.D., Ph.D.

Senior Vice President, Extramural Discovery Science

American Cancer Society

As the American Cancer Society’s Senior Vice President of Extramural Discovery Science, Christina Annunziata, M.D., Ph.D., leads a team of scientific directors and staff to identify the most innovative and promising research from research grant applications to end cancer as we know it for everyone. In addition to leading the grant peer-review process at the American Cancer Society, Annunziata builds and fosters critical relationships with cancer researchers across the nation and with international scientific communities.

Tomasz Beer, M.D.

Chief Medical Officer, Multi-Cancer Early Detection

Exact Sciences

Dr. Tomasz (Tom) Beer has served as Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences since August 2022. Dr. Beer also serves as Adjunct Professor of Medicine at the Oregon Health and Science University (OHSU) Knight Cancer Institute, where he sees men with prostate cancer. Until August of 2022, Dr. Beer was the Grover C. Bagby Endowed Chair for Prostate Cancer Research at the OHSU Knight Cancer Institute.

Paul Billings, M.D., Ph.D.

CEO

Biological Dynamics

Dr. Billings has devoted his life to studying and teaching medicine and genetics while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades of experience in health care, he has established key business partnerships to drive the adoption of innovative discoveries and commercial successes.

Kathy Bloomgarden

CEO

Ruder Finn

Kathy Bloomgarden is the CEO of Ruder Finn, one of the world’s largest independent public relations and creative agencies. She is known for her work positioning companies, CEOs, and senior management as leaders and change-makers in an era of disruption and accelerated transformation. She has more than 30 years of experience with dozens of top CEOs and business leaders across the health care, technology, and corporate sectors.

Justin Brueck

System Vice President, Innovation and Research

Endeavor Health

Justin Brueck is an experienced professional skilled in business development and strategy with in-depth experience in genomics and personalized medicine. He currently serves as Vice President for System Innovation and Research at Endeavor Health.

Brian Caveney, M.D.

Chief Medical & Scientific Officer

Labcorp

Dr. Brian Caveney is a distinguished leader in the healthcare sector, currently serving as the Chief Medical & Scientific Officer and the President of Early Development Research Laboratories at Labcorp. He is a licensed physician and attorney who holds an M.D. from the West Virginia University School of Medicine, a J.D. from its College of Law, and an M.P.H. from the University of North Carolina at Chapel Hill. He was recognized on Modern Healthcare‘s list of the 50 Most Influential People in Healthcare in 2020.

Josh Denny, M.D.

CEO, All of Us Research Program

U.S. National Institutes of Health

Josh Denny, M.D., M.S., is the CEO of the National Institutes of Health’s All of Us Research Program. All of Us seeks to enroll at least one million diverse participants to build an indispensable resource that accelerates precision medicine for all populations. Josh has been involved since the program’s inception. He was a member of the NIH Precision Medicine Initiative Working Group of the Advisory Committee to the Director, which developed the program’s initial scientific blueprint.

Okan Ekinci, M.D.

Senior Vice President, Global Head of Marketing & Innovation

Roche Information Solutions

Okan Ekinci serves as Senior Vice President and Global Head of Marketing & Innovation for Roche Information Solutions. In this capacity, Ekinci is responsible for coaching a global team of agile chapter leads responsible for product & solution marketing, innovation management, evidence generation, value delivery & implementation science, and a startup accelerator.

John Ellithorpe, Ph.D.

President

DNAnexus

John has spent his career driving innovative technology to improve people’s lives. At DNAnexus, John leads the product, engineering, science, services, and support teams. Prior, John was Chief Product Officer at Vantiq and co-founder, Chief Technology Officer, and Chief Product Officer at Model N.

Helmy Eltoukhy, Ph.D.

Co-Founder, Chairman, & Co-CEO

Guardant Health

Helmy Eltoukhy is the chairman and co-CEO of leading precision oncology company Guardant Health, which he co-founded in 2012 with Dr. AmirAli Talasaz. In 2007, Eltoukhy co-founded Avantome to commercialize semiconductor sequencing. Avantome was acquired by Illumina. While at Illumina, Eltoukhy served as senior director of advanced technology research. He developed novel chemistries, hardware, and informatics for genetic analysis systems. Eltoukhy received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.

Joe Franklin, Ph.D., J.D.

Head of Strategic Affairs

Verily

Joe Franklin leads the strategic affairs team at Verily and focuses on evidence generation strategy, including regulatory and privacy strategy at the intersection of clinical research and care. Before joining Verily in 2021, Joe held a variety of positions at the U.S. Food and Drug Administration, including service as a senior advisor on data and evidence initiatives.

Monika Frenzel, Ph.D.

Research Funding and Support Leader

European Partnership for Personalised Medicine

As the International Coordinator for the French National Research Agency, Monika Frenzel represents France on the European Partnership for Personalised Medicine, which is responsible for governing the advancement of personalized medicine on the continent.

Felice Freyer

President

Association of Health Care Journalists

Felice Freyer covers health care and medicine, seeking out the human stories behind medical science and policy. For The Boston Globe, she wrote a nine-part series that revealed the failures of addiction treatment and showed how some people nevertheless find their path to recovery. When the pandemic struck, Freyer embedded at a hospital coping with the crisis. In a story years in the making, Freyer described in September of 2023 how a revolutionary new drug for cystic fibrosis brought health and longer lives, but not without complications and sorrows.

David Goldstein, Ph.D.

CEO

Actio Biosciences

Dr. Goldstein is a human geneticist whose scientific career has focused on genetic diversity, the genetics of disease, and pharmacogenetics, leading to the co-founding of Actio Biosciences. He was previously the Director of the Institute for Genomic Medicine and a Professor of Genetics and Development at Columbia University, with the mission of integrating genetics and genomics into research, patient care, and education.

Mira Irons, M.D.

Associate Chief, Genetics and Genomics

Boston Children's Hospital

Dr. Mira Irons is a medical geneticist in Boston, MA, who specializes in the diagnosis, treatment, and management of hereditary diseases. She received her medical degree from McGaw Medical Center of Northwestern University and has been in practice for more than 20 years.

Jonathan Kish, Ph.D.

Head of Quantitative Sciences

Flatiron Health

Jonathan Kish is an epidemiologist and designer of novel research approaches to demonstrate real-world effectiveness, safety and patient impact of pharmaceuticals in oncology, immunology, neurology and rare diseases. He currently serves as Head of Quantitative Sciences at Flatiron Health.

Emily Kramer-Golinkoff

Co-Founder

Emily's Entourage

Emily Kramer-Golinkoff is a cystic fibrosis patient and co-founder of Emily’s Entourage, a nonprofit organization that raises funds for research for the 10 percent of cystic fibrosis patients who cannot benefit from genetically guided personalized medicines that have changed the treatment landscape for other patients with the disease. She earned bachelor’s and master’s degrees in communications and bioethics from the University of Pennsylvania.

Clifton Leaf

Former Editor-in-Chief

Fortune

Clifton Leaf, an adjunct professor of journalism at Columbia University’s Graduate School of Journalism, served as the Editor-in-Chief of Fortune from 2017 to 2021. During his tenure, Fortune won more than 70 top journalism prizes, substantially expanded its website, newsletter, premium subscription, podcast, and virtual conference businesses, and launched two new start-up businesses in career development and education, respectively.

Manoja Lecamwasam, Ph.D.

System Vice President, Intellectual Property, Strategic Life Sciences and Device Innovation

CommonSpirit Health

Manoja Lecamwasam is an experienced innovation executive with a demonstrated successful history of working in the hospital and health care industries. She currently serves as System Vice President for Intellectual Property, Strategic Life Sciences, and Device Innovation at CommonSpirit Health.

Mark Levin

Partner

Third Rock Ventures

Mark has been in the pharmaceutical, biotechnology, and venture capital fields for almost 50 years. He was co-founder, CEO, and chair of Millennium Pharmaceuticals, a leading company in personalized medicine. He was also founding co-director of the Mayfield Fund Biotech effort and co-founder of Third Rock Ventures.

Susanne Munksted

Chief Precision Medicine Officer

Diaceutics

Susanne is responsible for leading the knowledge and insights team of experts at Diaceutics. As the pharmaceutical business model continues to change towards precision medicine, there is a need to think differently and in an integrated way about the pharmaceutical and diagnostics business models from the top down. As Chief Precision Medicine Officer, it is Susanne’s role to drive this agenda and help Diaceutics’ clients understand the critical relationship and dependency between testing and treatment.

Brian Munroe

Founder, Board Member

Personalized Medicine Coalition

Brian Munroe is a founder of the Personalized Medicine Coalition. A 25-year veteran of health care public policy, advocacy, and communications, Brian’s areas of expertise include U.S. Food and Drug Administration-related legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine.

Lincoln Nadauld, M.D., Ph.D.

CEO

Culmination Bio

Lincoln Nadauld, M.D., Ph.D., is the CEO of Culmination Bio, a clinical insights company spun out of Intermountain Healthcare. Dr. Nadauld previously served as the Chief of Precision Health at Intermountain Healthcare, where he founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With this vision in mind, he oversaw the clinical implementation of precision genomics across Intermountain’s 24 hospitals and 160 physician clinics.

Joshua Ofman, M.D.

President

Grail

Joshua Ofman, M.D., is President at Grail, a multi-cancer early detection testing company. Josh also serves on the Board of Directors of Cell BT, Inc., an immunotherapy company focused on the discovery and development of innovative cancer therapeutics. Previously, Josh spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access and Policy. Prior to that, Josh was a faculty member in the Department of Medicine and Health Services Research at the UCLA School of Medicine.

Michael J. Pellini, M.D.

Managing Partner

Section 32

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology and healthcare. Prior to joining Section 32 in 2017, he served as CEO and Chairman of Foundation Medicine, a company that transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer. He transitioned to Foundation Medicine Chairman through the close of Roche’s acquisition of the company in August of 2018.

Glenn Pomerantz, M.D.

Chief Medical Officer

Point32Health

Glenn Pomerantz is Chief Medical Officer at Point32Health and is responsible for leading and advancing the organization’s clinical capabilities. In this role, he oversees clinical innovation, quality and accreditation, medical policy, and the Harvard Pilgrim Health Care Institute, which includes the Department of Population Medicine at Harvard Medical School.

Daryl Pritchard, Ph.D.

Senior Vice President, Science Policy

Personalized Medicine Coalition

Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the Personalized Medicine Coalition, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.

Sam Raha

Chief Operating Officer

Myriad Genetics

Sam Raha is Myriad’s Chief Operating Officer, focusing on driving profitable growth by strengthening operations and customer experience, including the patient and provider journeys and product innovations. He joined Myriad in December of 2023, bringing over 25 years of experience in the life sciences and diagnostics industries, including in general management roles leading research and development, operations, and commercial teams.

David M. Reese, M.D.

Executive Vice President, Chief Technology Officer

Amgen

Dr. David M. Reese is Amgen’s inaugural Executive Vice President and Chief Technology Officer, responsible for accelerating the use of technology and artificial intelligence across all facets of the company, as well as for the company’s global medical organization. Dr. Reese joined Amgen in 2005 and served as Executive Vice President, Research and Development, from 2018 to 2023.

Kate Sasser, Ph.D.

Chief Scientific Officer

Tempus

Dr. Kate Sasser is the Chief Scientific Officer of Tempus. Dr. Sasser brings over 20 years of experience in translational research and precision medicine in biological sciences across academia and the pharmaceutical and biotechnology industries. Prior to Tempus, she led the translational research, precision medicine, and research & development operations organizations within Genmab, a biotechnology company focused on developing transformative antibody therapeutics as medicine.

Christi Shaw

former CEO

Kite Pharma

From 2019 to 2023, Christi Shaw served as the CEO of Kite Pharma, a Gilead company specializing in the development of cancer immunotherapies. Ms. Shaw has also served as Senior Vice President of Eli Lilly Company, President of Novartis Pharmaceutical Corporation, and as a co-founder of the More Moments More Memories Foundation. From 2016 to 2017, she served as a full-time caregiver to her sister.

Ralph Snyderman, M.D.

Chancellor Emeritus

Duke University

Dr. Snyderman served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to 2004. During this time, he oversaw the development of the Duke University Health System and served as its first president and CEO. Dr. Snyderman’s focus is personalized health care and he continues to lead these efforts nationally from his position as Director of the Duke Center for Personalized Health Care.

Sapna Syngal, M.D.

Strategic Planning Director, Prevention and Early Detection

Dana-Farber Cancer Institute

Dr. Syngal is a practicing gastroenterologist at the Dana Farber Cancer Institute. As the Institute’s Strategic Planning Director for Prevention and Early Detection, she is also spearheading the next steps for one of the first clinical cancer genetics and prevention programs in the world. Dr. Syngal received her M.D. from McGill University in 1990 and completed her clinical training in internal medicine and gastroenterology at Brigham and Women’s Hospital.

Jacob Thaysen, Ph.D.

CEO

Illumina

Jacob Thaysen serves as CEO of Illumina and as a Director at Lasergen. Previously, he was the Senior Vice President & President of Life Sciences & Applied Markets at Agilent Technologies. He has also held positions as a Director at Gen9, as Vice President for Research & Development at Cytologix, and as Vice President of System Development, Research & Development, at Dako Denmark.

Apostolia M. Tsimberidou, M.D., Ph.D.

Professor, Department Of Investigational Therapeutics

The University Of Texas MD Anderson Cancer Center

Since joining the faculty at The University of Texas MD Anderson Cancer Center in 2001, Dr. Tsimberidou’s clinical research has focused on the development of therapeutic strategies for advanced hematologic malignancies and solid tumors. She has served as the Principal Investigator for 20 investigator-initiated clinical trials for the treatment of patients with advanced cancer.

Michael Vasconcelles, M.D.

Chief Medical Officer

ImmunoGen

Dr. Vasconcelles joined ImmunoGen in 2023 from Frazier Healthcare Partners, where he served as a Senior Advisor to the Life Sciences team. Prior to that, he was the Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a health technology company focused on accelerating cancer research and improving patient care. Before joining Flatiron, Dr. Vasconcelles served as Chief Medical Officer at Unum Therapeutics, a cell and gene therapy company.

Julia Vitarello

CEO

Mila's Miracle Foundation

Julia Vitarello is Founder and CEO of Mila’s Miracle Foundation. Upon learning that Mila’s disease had no cure and no child had ever survived it, Julia started the Foundation to initiate and fund novel treatments. She raised nearly $5 million in grass-roots efforts from over 6,000 supporters, while at the same time being a mom and caregiver. What began as a race to save Mila’s life has since turned into an opportunity to pave an entirely new treatment path for children with fatal genetic diseases.

Christopher J. Wells

Senior Vice President, Public Affairs

Personalized Medicine Coalition

As the Personalized Medicine Coalition’s Senior Vice President of Public Affairs, Christopher Wells oversees the development of PMC’s marketing and communications programs. He is the Director of the Annual Personalized Medicine Conference.

Janet Woodcock, M.D.

former Acting Commissioner

U.S. Food and Drug Administration

Janet Woodcock served as the Acting Commissioner of the U.S. Food and Drug Administration from January 20, 2021, until February 17, 2022. Dr. Woodcock began her FDA career in 1986 at the Center for Biologics Evaluation and Research (CBER). At CBER, she served as Director of the Division of Biological Investigational New Drugs and as Acting Deputy Director. She is widely regarded as one of the foremost pioneers in personalized medicine.

Michael Ybarra, M.D.

Chief Medical Officer

PhRMA

Michael Ybarra, M.D., is Chief Medical Officer at the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA advocates for public policies that support the innovative biopharmaceutical ecosystem. In support of key public policy priorities, Dr. Ybarra manages PhRMA teams responsible for coalition building, stakeholder engagement, and strategic partnerships domestically and internationally.